Diet vs. Drug: Which loses more fat?
Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested if a weight-loss drug (liraglutide) or eating less (calorie cutting) works better for losing fat and keeping muscle in people with obesity and prediabetes.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 582 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested if a weight-loss drug (liraglutide) or eating less (calorie cutting) works better for losing fat and keeping muscle in people with obesity and prediabetes.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 582 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Authors
Silver HJ, Olson D, Mayfield D, Wright P, Nian H, Mashayekhi M, Koethe JR, Niswender KD, Luther JM, Brown NJ
Related Content
Claims (5)
In adults with obesity and prediabetes, a 14-week diet creating a 390 kcal daily deficit leads to more weight loss and a greater improvement in body fat-to-muscle ratio than daily 1.8 mg liraglutide.
In adults with obesity and prediabetes, 14 weeks of eating fewer calories reduces belly fat by 9.5%, which is more than the 4.8% reduction seen with daily 1.8 mg of liraglutide.
In adults with obesity and prediabetes, reducing intake of simple sugars and carbohydrates during calorie restriction is linked to a 35.4% improvement in a measure of insulin resistance called HOMA-IR.
In adults with obesity and prediabetes, losing weight through calorie reduction maintains muscle mass, but taking 1.8 mg of liraglutide daily causes muscle mass to decrease.
In adults with obesity and prediabetes, taking 1.8 mg of liraglutide daily increases feelings of fullness and reduces self-reported desire to eat later, but does not lower the actual amount of calories consumed compared to dieting alone.